AOBiome Therapeutics, Inc. Email Format
Biotechnology ResearchMassachusetts, United States11-50 Employees
AOBiome Therapeutics, Inc. is a Cambridge, Massachusetts-based biotechnology company developing microbiome-based therapies to address inflammatory conditions that affect the skin, nasal passages, and other body systems. Founded in 2012 by Jamie Heywood and David Whitlock, the firm maintains a pipeline of clinical-stage candidates across several inflammatory indications, including acne, pediatric and adult eczema, episodic migraines, and allergic rhinitis, along with earlier-stage preclinical programs. The organization operates in the biotechnology research sector with a focus on translating microbiome science into therapeutic options for inflammatory diseases. In January 2024, AOBiome announced an exclusive license and development agreement with Maruho Co., Ltd. to develop and commercialize a topical biologic for dermatological indications, including atopic dermatitis, advancing toward global Phase 3 trials under the partnership.